Biohit Oyj (HEL:BIOBV)

Market Cap	40.75M -7.1%
Revenue (ttm)	16.13M +12.9%
Net Income	3.14M +38.4%
EPS	0.20 +31.8%
Shares Out	15.21M
PE Ratio	13.54
Forward PE	15.76
Dividend	n/a
Ex-Dividend Date	n/a

Volume	10,091
Open	2.740
Previous Close	2.700
Day's Range	2.670 - 2.740
52-Week Range	2.200 - 3.780
Beta	0.58
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 5, 2026

About Biohit Oyj

Biohit Oyj, a biotechnology company, manufactures and sells bind acetaldehyde, diagnostic products, and systems for diagnostic analysis for the use of research institutions, healthcare, and industry worldwide. The company offers GastroPanel quick test NT, a rapid and quantitative immunochromatographic test for the detection of Helicobacter pylori and atrophic gastritis; GastroPanel test, a blood test for diagnosis of the function and structure of stomach mucosa; GastroSoft, a software application designed to assist clinicians and general practi...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 1988
• Employees: 46
• Stock Exchange: Nasdaq Helsinki
• Ticker Symbol: BIOBV

Financial Performance

In 2025, Biohit Oyj's revenue was 15.73 million, an increase of 10.14% compared to the previous year's 14.28 million. Earnings were 2.74 million, an increase of 6.62%.

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Aug 7, 2026

Data Sources Report a data error